Nieuws

jul
19

IMI launches call fifteen and sixteen

The JTI Innovative Medicines Initiative 2 (IMI JU) has launched its fifteenth and sixteenth call for proposals. The indicative budget available for the 15th call with identifier H2020-JTI-IMI2-2018-15-TWO-STAGE is € 386,722,862. The Stage 1 submission deadline is October 24, 2018. The indicative budget available for the 16th call with identifier H2020-JTI-IMI2-2018-16-SINGLE-STAGE is € 46,900,000. The submission deadline is October 24, 2018.

Call fifteen includes eight topics:

Topics under the IMI2 Antimicrobial Resistance (AMR) Accelerator programme

 

Call sixteen includes seven topics:

 

The goal of the IMI2 is to develop next generation vaccines, medicines and treatments, such as new antibiotics. It will build on the successes and lessons learnt under IMI. Like IMI, it will bring together companies, universities, public laboratories, innovative small and medium-sized enterprises (SMEs), patient groups and regulators in collaborative projects that will pave the way for breakthrough vaccines, medicines and treatments to tackle Europe’s growing health challenges, and secure the future international competitiveness of Europe's pharmaceutical industry.

Terug naar overzicht